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Abstract Familial microscopic hematuria (MH) of glomer-
ular origin represents a heterogeneous group of monogenic
conditions involving several genes, some of which remain
unknown. Recent advances have increased our understand-
ing and our ability to use molecular genetics for diagnosing
such patients, enabling us to study their clinical character-
istics over time. Three collagen IV genes, COL4A3,
COL4A4,a n dCOL4A5 explain the autosomal and X-
linked forms of Alport syndrome (AS), and a subset of
thin basement membrane nephropathy (TBMN). A number
of X-linked AS patients follow a milder course reminiscent
of that of patients with heterozygous COL4A3/COL4A4
mutations and TBMN, while at the same time a significant
subset of patients with TBMN and familial MH progress to
chronic kidney disease (CKD) or end-stage kidney disease
(ESKD). A mutation in CFHR5, a member of the
complement factor H family of genes that regulate
complement activation, was recently shown to cause
isolated C3 glomerulopathy, presenting with MH in
childhood and demonstrating a significant risk for CKD/
ESKD after 40 years old. Through these results molecular
genetics emerges as a powerful tool for a definite diagnosis
when all the above conditions enter the differential
diagnosis, while in many at-risk related family members,
a molecular diagnosis may obviate the need for another
renal biopsy.
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Introduction
Microscopic hematuria (MH) of glomerular origin is a
symptom of a heterogeneous group of conditions that can be
either sporadic and acquired, or familial and inherited related
to several genes, some of which remain unknown. As a safe
general guideline, familial MH is best confirmed by demon-
strating microhematuria in a number of first-degree relatives,
each one tested positive at least twice at different intervals.
Familial MH usually develops in early childhood and
continues until late in life and until death, characterized by
an unpredictable risk of progression to chronic kidney disease
(CKD) or by age-dependent penetrance.
MH of hereditary or non-hereditary nature is a frequent
finding in the general population, loosely defined as the
presence of over 3–5 red blood cells per high power field in
the light microscope. Glomerular origin MH can be
distinguished from non-glomerular with the use of phase
contrast urine microscopy. MH persists for life, sometimes
intermittently; therefore the more often an individual is
tested for hematuria, the more likely it is to be found.
It has been reported that the frequency of MH can be as
high as 1%, although different reports have mentioned
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is unknown what portion of MH in the general population
is of hereditary nature. In this review, we focus on two
major forms of MH, the heritable collagen IV nephropa-
thies and the newly revisited C3 glomerulopathy caused by
mutations in the CFHR5 gene. For reasons of completeness,
we should mention that mutations in the MYH9 gene
(nonmuscle myosin heavy chain IIA) define a spectrum of
rare autosomal dominant macrothrombocytopenias that
present as familial hematurias. There are four clinical
entities: the May-Hegglin anomaly, and the Fechtner,
Sebastian, and Epstein syndromes, which represent a
variable expression of a single illness, and they share
ultrastructural features with AS while they are associated
with sensorineural deafness [2–4]. Hematuria may also be
the presenting symptom of other non-glomerular capillary
diseases, such as polycystic kidney disease, hypercalciuria,
and other familial forms of urolithiasis.
An episode of macroscopic hematuria in childhood or
adolescence, even painless, rarely passes unnoticed, and
invariably leads to an urgent urology or nephrology
consultation. The differential diagnosis is wide open, and
IgA nephropathy (IgAN) may be the commonest cause. On
the contrary, pure MH often remains unnoticed for a long
time and initially not enough attention is paid to its
presence. What is important to realize is that persistent
MH, occasionally with episodes of macroscopic hematuria
may be familial and hereditary and the investigation of a
child or young adult with continuous MH may not be
complete unless both parents and all siblings have had a
morning specimen of urine examined with a microscope or
a suitable urine tape, as a routine procedure. A careful
family history is also essential. When these two steps are
done, an increasing number of families with hereditary
hematuria are encountered.
For patients with inherited continuous MH with or
without episodes of macroscopic hematuria and a patho-
physiology that centers on abnormalities in the structure of
the glomerular basement membrane (GBM), the differential
diagnosis includes: (1) the X-linked male Alport syndrome
patients [5–9], (2) all related heterozygous female carriers
of an X-linked mutation that invariably exhibit lifelong MH
[6, 7, 9–11], (3) the autosomal recessive male and female
Alport patients [6, 7, 12], (4) all male and female COL4A3/
A4 heterozygous carriers that exhibit thin basement mem-
brane nephropathy (TBMN) with lifelong MH [6, 7, 13–
15], and (5) since 2009 the newly described CFHR5
nephropathy with normal GBM and isolated C3 mesangial
deposits, a hereditary nephritis related to a loss-of-function
mutation in one of the genes of complement Factor H
family, CFHR5, which has a pivotal role in the regulation of
the alternate complement pathway [16, 17]. Yet other causes
may exist, as in our center alone we have over 35 families
with apparent hereditary hematuria where no definite cause
has yet been identified. IgAN, currently the most common
glomerulonephritis presents with episodes of macroscopic
hematuria after upper respiratory tract infections (URTI),
followed for long periods of time by MH. There is usually
no family history but familial clustering has been observed,
although no specific genes have been cloned. A recent
study of a large IgAN family localized a novel susceptibil-
ity locus to chromosome 2q36 but no gene has yet been
cloned [18]. Also, genome-wide association studies using
sporadic cases mapped five susceptibility genes, three in the
major histocompatibility complex, one on chromosome
22q12, and a common deletion of genes CFHR1-CFHR3 at
chromosome 1q32 that are known to be implicated in
complement regulation [19].
What is of great interest is the currently unpredictable
long-term progression of these hematuric patients to
proteinuria, CKD and ESKD, most probably owing to the
negative contribution of various unknown modifying
factors, presumably of genetic and/or environmental nature.
Equally interesting is the fact that the underlying patho-
physiology of these microhematuria is not always clear.
Unfortunately, and until very recently, these young familial
hematuric patients were not routinely submitted to an early
renal biopsy to include electron microscopy. Instead, a
"wait-and-see" approach until proteinuria developed was
followed by many experts [20]. The recent recognition of
the pure isolated C3 nephropathy and the additional
possibility of TBMN may now help to shift the clinician’s
decision towards an earlier renal biopsy in combination
with molecular genetics studies.
Molecular biology of collagen IV nephropathies
Most Alport cases (85%) are caused by mutations in the X-
linked gene, COL4A5, which encodes the α5 chain of type
IV collagen, the most abundant structural protein in the
GBM. The remaining 15% of cases are caused by
autosomal recessive mutations in the genes that encode
the α3 and α4 chains of the type IV collagen, COL4A3/
COL4A4 [21, 22]. Collagen type IV, as all collagens, is a
trimer formed by combinations of three of the six alpha
chains, α1-α6. Genes COL4A1 and COL4A2 map to
chromosome 13q34, COL4A3 and COL4A4 map to
chromosome 2q36–q37, and COL4A5 and COL4A6 map
to Xq22-23. All six genes are encoded in nearly 50 exons
and close to 1,600 amino acids, and consist of an N-
terminal 7S domain, a C-terminal non-collagenous (NC1)
domain and a large collagenous domain in between,
containing the characteristic Gly-X-Y repeat, common to
all collagens. All six alpha chains contain 22–26 natural
interruptions of the Gly-X-Y repeats, spread throughout
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regions of specific function and/or ligand binding sequen-
ces, of significance to its structural role in the basement
membrane. Although there are many possible combinations
among the six alpha chains, only three are biologically
compatible and found in basement membranes. These are
composed of α1α1α2, α3α4α5, and α5α5α6. Type IV
collagen participates in forming networks interacting with
additional important components of the basement mem-
branes, such as laminin and nidogen [23, 24]. As a
component of the glomerular filtration barrier, along with
the endothelial cells and the podocytes, basement mem-
branes play a crucial role as a selective filter, based on
molecular size and charge. A damage of the basement
membrane or inherited defects such as mutations in type IV
collagen lead to the abnormal passage of red blood cells in
the urine.
Clinical signs, GBM histology, and genetics of X-linked
Alport syndrome
X-linked Alport syndrome is one of the most severe
inherited glomerulopathies, characterized by alternating
thinning and thickening of the GBM as well as splitting
and lamellation of the lamina densa. At a young age,
affected hemizygote males and heterozygous female car-
riers may present initially with uniform thinning of the
GBM, which in males progresses rapidly with age to a
more severe thickened and lamelated picture accompanied
by the onset of proteinuria, hypertension, and renal failure,
usually reaching ESKD between adolescence and the third
decade of life. About 82% of patients develop sensorineural
hearing loss and about 44% develop ocular abnormalities
[25].
Over the past two decades, after clinical and molecular
investigation of hundreds of X-linked Alport cases, much
experience has been accumulated regarding the important
correlation of genotype to phenotype. Based on the age at
onset of ESKD and the rate of clinical progression, two
forms of X-linked Alport are usually recognized [26], the
classical, well-recognized "juvenile" type and the "adult"
type. In the former, ESKD ensues rapidly in men at about
20 years of age. In the "adult" type, the age at ESKD
extends to the late 20s or even the 30s, 40s, and 50s,
especially in patients inheriting some milder COL4A5
missense mutations (see below). In young adult males
who carry milder missense mutations, areas of thickening
and thinning may coexist or only thinning may be present,
with or without splitting, making a definite histological
diagnosis of Alport syndrome occasionally difficult. Many
researchers have stressed this [8, 27–30]. One could point
out that this clinical presentation resembles the one
exemplified by some heterozygous carriers of mutations in
the autosomal COL4A3/COL4A4 genes that suffer from
TBMN and late onset proteinuria, CKD, and ESKD.
There are five studies, one in entire Europe with the
European Community Alport Syndrome Concerted Action
study (ECASCA) [10], and one each in Germany [26],
Slovenia [7], China [31], and very recently in the USA
[32], describing the whole spectrum of clinical phenotypes
from over 500 COL4A5 mutations and confirm that the
position and type of each mutation may dictate to a large
extent the severity of Alport and how soon ESKD may
ensue. Gross et al. (2002) [26] proposed the following
classification of phenotypes of X-linked Alport patients: (a)
type S (Severe), characterized by juvenile-onset ESKD
(∼20 years of age), 80% incidence of hearing loss and 40%
incidence of ocular lesions. This classical picture is caused
by large rearrangements, premature stop, frameshift, donor
splice site, and mutations in the NC1-domain (b) type MS
(Moderate–Severe), including patients that progress to
ESKD at age ∼26 and present lower frequencies of the
extrarenal manifestations, implicating non-glycine missense
mutations, glycine substitutions in exons 21–47, in-frame
and acceptor splice site mutations, and (c) type M
(Moderate), associated with glycine substitutions in exons
1–20 and characterized by late-onset ESKD (after the age
of 30), 70% hearing loss, and less than 30% ocular lesions.
Bekheirnia et al. (2010) [32], in a cohort of US patients
with X-linked Alport, support the proposition of Gross et
al. (2002) [26] that the most aggressive phenotypes are
caused by truncating mutations, large and small deletions
and splice mutations.
A prime example of a COL4A5 mutation that is
associated with a mild hematuric phenotype is a substitu-
tion of glycine at position 624 by aspartate (G624D). This
mutation probably represents a recurrently mutated position
or it may be an example of a trans-national founder
mutation. It was firstly described by Martin et al. (1998)
[33] in a single family with a mild presentation and by
Barker et al. (2001) [34] in a separate family. More recently,
Slajpah et al. (2007) [7] reported mutation G624D in a total
of 13 patients (nine females, four males) belonging to six
small unrelated Slovenian kindreds. One family was
diagnosed with adult-onset Alport based on EM findings
and five were diagnosed as benign familial hematuria
(BFH) until molecular genetics settled the diagnosis. They
appear to be the first to propose that "adolescence ESKD
and BFH may represent two opposite poles of the spectrum
of hereditary COL4A5 nephropathies" [7], thus resembling
the TBMN nephropathy resulting from COL4A3 and
COL4A4 heterozygous mutations, confirmed recently in a
large cohort from our center [15, 35].
We had a similar experience with two Greek families,
one from Athens and one from Thessaloniki, who segre-
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presented with late-onset renal failure, very likely a
characteristic of this mutation. In family GR4209, a male
patient reached ESKD at the age of 39 with sensorineural
deafness. Another affected male showed hematuria and
proteinuria accompanied by sensorineural deafness but his
serum creatinine was normal at 1.03 mg/dl, at the age of 30.
In the other family, GR4211, two brothers inherited the
mutation. One reached ESKD at 50 years old without
deafness, while his renal biopsy showed FSGS with
uniform thinning of the GBM that included focal splitting.
His two daughters have documented MH in their twenties.
His brother is proteinuric with mildly reduced GFR and no
deafness at 55 years old. The clinical and renal biopsy
findings, including EM, in both families differ from classic,
adolescence, and adult type X-linked Alport. Affected
males developed ESKD late in life, after ages 39 to 50, or
not at all, resembling the female carriers of X-linked
COL4A5 nephropathy or the heterozygous carriers of
mutations in COL4A3/COL4A4. In at least one renal biopsy
that included EM there was TBMN and also FSGS [36].
Interestingly, we identified another similar COL4A5
mutation in two Cypriot families also associated with mild
disease. This mutation, P628L in exon 25, is located very
close to the G624D and affects a Y-position proline, which
is substituted by leucine. This mutation also demonstrates a
milder phenotypic expression. Among eight men carrying
the mutation, five developed ESKD at ages 30, 34, 37, 45,
and 57 years old. The 57-year-old patient also had diabetes.
Another patient exhibited keratoconus. Three men had
CKD of mild degree. Sensorineural deafness was found in a
man with ESKD and in another with mild CKD who at the
age of 48 maintains a serum creatinine of 2.5 mg/dl. His
renal biopsy shows TBMN with FSGS. Six female carriers
exhibit MH and two have additional non-nephrotic protein-
uria. A recent biopsy of a 19-year-old female demonstrated
TBMN in the presence of early FSGS. The progression to
ESKD in the affected males is slow and delayed, very
similar to patients carrying mutation G624D. Mutations
G624D and P628L are very near the 12th natural
interruption of the Gly-X-Y repeats in the COL4A5 chain,
an observation that might offer an explanation for the
associated milder phenotypes. Both mutations occurred on
either side of a G1G natural interruption. Mutation G624D
converts the G1G interruption into a G4G interruption,
allowing the assumption that the destabilization of the
collagen triple helix is not as dramatic as when a similar
substitution occurs elsewhere in the collagenous domain.
Similarly, mutation P628L represents a substitution of a
hydroxyproline residue at the Y position of a tripeptide unit
right after the G1G interruption. It can be hypothesized that
some mutations, such as these near natural interruptions, do
not disrupt drastically the zipper-like formation of the triple
helix, which commences at the C-terminal end, or interfere
less with the binding of putative ligands in the matrix
milieu (Fig. 1)[ 36].
Along the same line, a recent case report described a male
patient with a COL4A5 mutation that substitutes glycine with
valine at amino acid residue 1000 (G1000V) [37]. The
patient, aged 38, presented with only BFH, which segregated
in the family. Based on all the above, one expects that many
more similar families may exist worldwide remaining
unnoticed, largely because older affected males with MH are
not considered to result from X-linked COL4A5 mutations
and are therefore not investigated accordingly. A careful
consideration of the inheritance pattern by drawing a detailed
pedigree can always help. A male-to-male transmission
certainly excludes X-linked inheritance while a negative
epidermal BM immunostaining for the α5 chain confirms
X-linked AS. Unfortunately, a normal skin immunostaining
does not exclude AS. A wider family history of sensorineural
deafness and ocular abnormalities supports this diagnosis but
cannot confirm it unequivocally, especially in smaller pedi-
grees [4]. In these, and many similar cases, the differential
diagnosis based on clinical symptoms only will not resolve it
and molecular investigation can be of great help.
Fig. 1 Schematic representation of the collagen IV triple helical
molecule. The vertical lines along the triple helix represent the
positions of the natural Gly-X-Y interruptions. Note that mutations
G624D and P628L occurred near the 12th interruption of the α5
chain. Essentially, the G624D mutation converted the G1G interrup-
tion into a G4G one, while the P628L may affect the folding of the
triple helix as it zippers from the C-terminal towards the N-terminal.
Mutation F222C, substituting a cysteine for phenylalanine, occurred in
the second natural interruption of a G4G type [38]
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large American family with mutation F222C in the
COL4A5 gene, where male patients presented with a novel
severe glomerulopathy that rapidly progressed to ESKD at
ages 10–22 years old. The mutation was within a G4G
interruption of the collagenous domain, substituting a
conserved phenylalanine residue, thereby attributing an
unknown functional role. Interestingly, the authors empha-
size the absence of typical AS clinical and biopsy findings.
The symptoms included proteinuria and variable hematuria
while the biopsy showed global and segmental glomerulo-
sclerosis, mesangial hypercellularity and GBM immune
complex deposition, quite unusual for AS. There were no
typical Alport biopsy findings such as GBM alternate
thinning and thickening nor any GBM splitting and
lamellation (Fig. 1).
Finally, it should be mentioned that according to the
recent report by Hanson et al. (2010) [9], even in the
presence of an incomplete picture and only two diagnostic
criteria for Alport syndrome, mutations can be found in
the COL4A5 gene in up to 64% of the patients. This
supports our hypothesis that patients with milder pheno-
types might harbor such mutations and deserve molecular
investigation.
Thin basement membrane nephropathy (TBMN)
and phenotypic heterogeneity
The term TBMN has been used to describe the histological
EM situation where the GBM demonstrates pure thinning
of the GBM, compared to normal. The normal GBM
thickness varies from 300–400 nm, and this variation is
attributed to individual variability, age, gender, and the
center performing the measurement. Until recently, TBMN
was invariably considered to lead to familial BMH [8, 30],
with a positive family history and no episodes of
macroscopic hematuria. Ocular abnormalities, hearing loss
and renal impairment were classically considered to be
absent from the syndrome of BFH and long-term prognosis
was deemed excellent. Universal thinning of the GBM is
characteristic of the heterozygous carriers of COL4A3/
COL4A4 mutations. In contrast, the much rarer homozy-
gous or compound heterozygous of such mutations in the
COL4A3/COL4A4 genes develop the classical autosomal
recessive Alport syndrome course with early proteinuria
and hypertension, reaching ESKD by late adolescence and
the early 20s.
Since the first report by Lemmink et al. (1997) [39] that
described the first COL4A4 mutation in a patient with
TBMN, numerous publications supported the essential
synonymy between TBMN due to heterozygous mutations
in COL4A3/COL4A4 genes and BFH [7, 13, 40–49].
However, some previous investigations that had not
attracted the proper attention had alerted to the fact that
not all patients with heterozygous COL4A3/COL4A4
mutations would follow a benign course. Instead, they
reported on patients who started off with TBMN on biopsy
and MH and slowly progressed to proteinuria, hyperten-
sion, and chronic or ESKD [13, 50–54]. In some of those
works, the authors invoked the association with another
glomerulonephritis, such as IgAN, FSGS, minimal change
disease, mesangioproliferative glomerulonephritis and
others ([55] and references therein).
In 2007, we presented the largest series of patients with
three founder heterozygous mutations in either the COL4A3
or the COL4A4 where a significant percentage had
demonstrated the dual diagnosis of TBMN and FSGS, with
progression to renal failure and ESKD. Specifically, those
data along with additional unpublished results show that in
our cohort of 180 Cypriot patients, nearly 50% proceed to
CKD/ESKD while 13% of all develop ESKD, usually after
50 years old [15, 35, 56]. In detail, of 90 patients over 50
years old, 48 have CKD (53%), while 23 of the 48 have
ESKD (23/90, a percentage of 25%) (Fig. 2, Table 1). These
findings have recently been supported by another indepen-
dent brief report [57], and certainly cast serious doubt on
the commonly used term of "benign familial hematuria"
with excellent prognosis. It is more than obvious nowadays
that not all COL4A3/COL4A4 mutation carriers will enjoy a
good prognosis for life and after the age of 30–40s. A
closer follow-up is necessary in order to identify early
enough those predisposed to adverse progression. Based on
these findings and considering that a great many of our
patients carry a common founder mutation, we hypothesize
that modifier genes, perhaps in addition to unknown
environmental factors, contribute to this inter- and intra-
familial variability and unpleasant progression. It is worth
mentioning that among the 180 patients in this TBMN
cohort, 134 bear mutation G1334E, thereby minimizing
genetic background variability ([15] and unpublished
results).
It is evident that familial hematuria encompasses a wide
spectrum of COL4 mutations, affecting the α3, α4, and α5
chains and a renal biopsy with molecular genetic analysis
are always important to establish and define accurately the
underlying pathophysiology. Once the molecular diagnosis
is confirmed in a pedigree, molecular genetics and DNA
testing may avert the need for further renal biopsies in
affected relatives. Above all, however, it is the realization
that truly long-term follow-up with regular check-ups is
necessary to ensure that the patient receives the best
possible care. The appearance of only low-grade proteinuria
is not a comforting sign and it is a warning that progression
to a more severe phenotype, affecting renal function, may
follow.
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A recent genetic discovery in familial hematuria has been
the description of heritable C3 glomerulonephritis as a
result of mutations in the CFHR5 gene (CFHR5 nephrop-
athy), by a large collaborative effort [16]. The CFHR5 gene
belongs to a family of five genes (CFHR 1–5) clustered on
chromosome 1q32, encoding for proteins that take part in
the alternative complement pathway regulation. Comple-
ment factor H (CFH) and CFH-related proteins 1–5 share a
subset of homologous domains, about 60 amino acids long,
the sequence consensus repeats. CFHR5 binds C3b and it
has been localized at the glomerular deposits of patients
with glomerulonephritis, demonstrating a deposition pattern
similar to C3 [58, 59].
This new hereditary form of MH had been described
before but its hereditary nature and pathophysiological
connection to the complement alternate pathway system
had not been recognized [60–62]. Similarly, as regards its
histology, mesangial C3 glomerulopathy has been known at
least since 1980 from published reports in Europe and
Japan, while more recently, loss-of-function mutations in
important regulatory proteins such as CFH, complement
factor I and membrane cofactor protein, have been detected
in patients with inherited nephropathies characterized by
isolated C3 mesangial deposits [63–68]. As the pathological
pattern of glomerular inflammation is associated with
dysregulation of the alternative complement pathway, there
is no requirement for antibody-antigen complex to start the
activation of C3 cascade and essentially no immunoglobu-
lins are detected in the damaged glomerulus.
CFHR5 nephropathy is an autosomal dominant disease
and is clinically characterized by continuous MH while
some 25% of the patients also present with synpharyngitic
macroscopic hematuria in childhood and adolescence
associated with infection and pyrexia. Based on a recent
description of a large patient cohort, in addition to
hematuria, 80% of patients, particularly males, develop
proteinuria, hypertension and chronic or ESKD, a progres-
sion that seems to start slightly earlier than in TBMN
patients and follows a faster course [16, 17]. The main
finding in 17 available renal biopsies was mild increase in
mesangial matrix and cells, with isolated C3 deposits in the
mesangium and the sub-endothelial area, and no immuno-
globulin deposition. GBMs were of normal thickness.
Until the end of 2010, we screened genetically 163 at-risk
subjects from 16 affected Cypriot families. Of these, 105
(64%) carry a common mutation, a duplication of exons 2–3
[16]. Of these 105 mutation carriers (MC), nine subjects
(8.5%) at various ages (12–88 years old) have as of yet no
urinary abnormalities, a clear indication of reduced pene-
trance. The great majority (62 patients, or 59%), only show
MH, while 34 patients have developed additional proteinuria.
Of these 34 proteinuric patients, 30 have gone on to develop
renal failure and 18 have reached ESKD. Of great interest is
the striking gender difference, because 15 of the 18 patients
with ESKD are males (83%) and only three are females
(17%) (Fig. 3, Table 2). Eleven patients received 13 renal
transplants with excellent survival between 1 and 23 years.
It is of great interest that nearly all male patients who
have reached ESKD have exhibited in childhood and
adolescence additional episodes of macroscopic hematuria
Fig. 2 Prevalence of symptoms
amongst 180 TBMN mutation
carriers, according to age. Under
the age of 30, only microhema-
turia was encountered. After
the age of 30, proteinuria
complicated by CKD and ESKD
developed in a significant
degree (updated from [15],
used with permission)
Mutation
carriers (MC)
All MC with negative
urine findings
Micro
hematuria
ONLY
MH +
proteinuria No CRF
Proteinuria +
CRF/ ESRD
ESRD
180/180 9/180 94/180 23/180 54/180 23/180
100% 5% Reduced
penetrance
52% 13% 30% 13%
Table 1 Clinico-pathological
findings in 180 patients of 15
Cypriot pedigrees with an
inherited COL4A3 or
COL4A4 mutation
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is very similar to IgA nephropathy, a fact that on several
occasions caused debate as to whether the renal biopsy had
actually failed to demonstrate the anticipated IgG/IgA
deposits. In one affected family in particular, where a
daughter first exhibited episodes of macroscopic hematuria
following a URTI, no renal biopsy was carried out, and a
report was sent to the referring physician describing it as a
classical case of IgG/IgA Berger’s disease. The situation
became more complex when her younger brother, 9 years
later, also developed episodes of macroscopic hematuria at
19 years old, associated with a URTI. The diagnosis of
probable familial Berger’s disease changed to CFHR5
nephropathy when the molecular test in 2009 proved
positive. Their father carried the CFHR5 mutation and
had MH that he was not aware of. It is also likely that some
cases that initially are thought to have TBMN, without a
biopsy, and test negative for COL4A3/COL4A4 mutations,
actually may turn out to have C3 nephropathy. We had one
such family in our cohort.
It is of interest that so far all patients described are of
Greek-Cypriot origin and they all carry the same founder
mutation, a duplication of CFHR5 exons 2–3[ 16, 17]. This
facilitates tremendously the diagnosis by a simple poly-
merase chain reaction amplification test, thereby also
obviating the need for a renal biopsy to other family
members who present with suspicious similar symptoms.
One anticipates that since the histological changes of pure
C3 nephropathy have been described in patients from
several countries all over the world, the Greek-Cypriot
mutation or other similar CFHR5 mutations will be
discovered in these patients in the next few years. To date,
however, the prevalence of this disease in populations
outside Cyprus is unknown.
Conclusions
Pure familial MH in early childhood cannot distinguish
between the Alport syndrome, either X-linked or autosomal
recessive, the TBMN phenotype, the CFHR5 nephropathy
and the several other, yet unknown causes of familial
hematuria. A detailed family history is essential, looking
particularly at (a) the pattern of inheritance, (b) the age at
which other family members developed proteinuria, CKD,
and ESKD, and (c) the presence of sensorineural deafness
and/or ocular defects. Investigations should start with the
usual tests for kidney function, urine analysis for additional
proteinuria, and molecular genetics aimed at identifying
either a COL4,o rCFHR5 gene mutation. These inves-
tigations should be extended to the parents, siblings, and
more distant relatives. In our opinion, in established
familial cases, an early renal biopsy including EM is
always useful and desirable and should be encouraged in
at least one affected family member with MH. In addition to
the histological evaluation, a kidney biopsy may direct the
line of molecular investigations, in view of the genetic
heterogeneity underlining familial MH. A successful
molecular diagnosis reduces or abolishes the need for
additional diagnostic biopsies. Unfortunately, there is no
consensus among nephrologists regarding the need of an
early renal biopsy in patients with familial hematuria. Some
are advocates of a biopsy even in the presence of isolated
continuous MH while others are opposed to it until
Fig. 3 Prevalence of symptoms
among 100 CFHR5 mutation
carriers, according to age. Under
the age of 30, only microhema-
turia was encountered. After
the age of 30, proteinuria
complicated by CKD and ESKD
developed in a significant
degree (especially in males)
(updated from [17], used
with permission)
Mutation
carriers (MC)
All MC with negative
urine findings
Hematuria
ONLY
Hematuria +
proteinuria, No CRF
Proteinuria +
CRF/ ESRD
ESRD
105/105 9/105 62/105 4/105 30/105 18/105
100% 9% Reduced
penetrance
59% 4% 29% 17%
Table 2 Clinico-pathological
findings in 105 patients of 16
Cypriot pedigrees with the
CFHR5 exons 2–3
duplication
Pediatr Nephrol (2012) 27:1221–1231 1227proteinuria develops [69–71]. In a relevant algorithm by
Kashtan [4], a kidney biopsy is recommended before
molecular testing and after a α5(IV) positive skin biopsy.
As regards the limitations of the biopsy, it is emphasized
by Haas (2009) [8] that EM alone cannot distinguish
between TBMN, the heterozygous carrier state of XLAS,
autosomal recessive Alport syndrome and early stages of
XLAS. This is where the molecular approach can prove
instrumental in the differential diagnosis, and especially so
when previous studies have established the affected
haplotype or the responsible germinal mutation. It is worth
emphasizing that in cases where familial hematuria is
diagnosed and a mutation is found, the first and easiest
non-invasive investigative test for the next patient who
comes down with additional proteinuria or other relevant
symptoms should be a molecular analysis to confirm or
exclude the familial condition. An algorithm for the series
of molecular tests based on present-day knowledge of the
genetics of familial hematuria is proposed in Fig. 4.
Correct family counseling, excellent medical care, and
good long-term follow-up are top priorities. Classical
adolescent Alport syndrome or Alport syndrome reaching
ESKD later in the late 30s is now well known and accepted,
but it is important to emphasize the accumulating evidence
according to which single amino acid substitutions in the
COL4A5 gene, such as the G624D and P628L, may not
always lead to early renal failure. Instead, a mild hematuric
syndrome may persist late in life with minimal proteinuria
and renal impairment. Clinicians should be aware that a
subset of patients with familial hematuria, thin membranes,
and late-onset ESKD may also be explained by COL4A5
mutations. This X-linked disease status may not satisfy the
classical Alport syndrome clinical diagnosis but rather an
X-linked TBMN diagnosis. It is presently unknown how
widespread this is but several reports already have
introduced this notion [7, 36, 37].
Available evidence since the original work by Lemmink
et al. (1996) [39] indicates that most patients with micro-
hematuria and TBMN result from heterozygous COL4A3/
COL4A4 mutations and the first 3–4 decades of life are
indeed characterized by pure ΜΗ alone. From then on,
however, some 50% of these patients will follow a different
course, progressing into proteinuria and CKD. Recent data
on a large Cypriot cohort [15] confirm that not all TBMN
cases will follow a benign course and regular annual check
ups, to include tests for proteinuria should alert patients and
physicians to the possibility of progression into CKD and
eventually ESKD. A renal biopsy should be seriously
considered at this stage and appropriate measures such as
statins, ACE inhibitors, and possibly cyclosporin should be
entertained to arrest the evolution of the disease. It is fair to
say that apart from the large patient cohort from Cyprus, in
several reports by other investigators, the majority of
TBMN patients follow a benign course. There might be
genetic and/or environmental factors to explain these
disparate findings and hopefully future work and longer
follow-up in other populations in view of our results, will
enlighten this issue and provide the correct answers.
Fig. 4 Algorithm for molecular
testing of patients belonging to
families segregating glomerular
microscopic hematuria. A kid-
ney or a skin biopsy may be
performed before or after the
molecular analysis depending on
the clinical status or disease
progression of the patient, for
histological evaluation. An early
biopsy may also help direct
molecular testing. In most, but
certainly not all, families where
a diagnosis has been established
by molecular means, a simple
molecular testing of the subject
under study, for detecting the
responsible affected haplotype
or germinal mutation, might be
adequate. A molecular diagnosis
will acquire a superb position in
CFHR5 and collagen IV
nephropathies diagnosis and
treatment if early intervention
proves decisive for disease
prevention
1228 Pediatr Nephrol (2012) 27:1221–1231The list of causes of familial MH is still incomplete
and good family studies, careful renal biopsies and
molecular genetics are needed to solve the puzzle of
the remaining causes of familial hematurias. In this
respect, the identification of the CFHR5 mutation is a
recent development that provides an insight into a
histological finding known but not understood for over
40 years. At the same time, it provides possibilities for
more specific and efficient therapies for patients who were
programmed to end in ESKD. This advance also opens up
possibilities for more research in the CFHR5 gene, the
alternate complement pathway and the entire complement
system which may be associated with other forms of
isolated C3 glomerulonephritis, atypical hemolytic uremic
syndrome, dense deposit disease and other forms of yet
unknown familial GN [72].
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